Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study mechanisms of blood pressure lowering of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women

- candidate number17702
- NTR NumberNTR4590
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR9-mei-2014
- Secondary IDsNL49102 CCMO
- Public TitleA randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study mechanisms of blood pressure lowering of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women
- Scientific TitleA randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study mechanisms of blood pressure lowering of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women
- hypothesisWe hypothesize that formerly pre-eclamptic women have persistently increased angiotensin II sensitivity, sodium sensitivity, insulin resistance and sympathetic nerve activity together leading to susceptibility for early renal disease and subsequently hypertension, chronic kidney disease and cardiovascular disease. Possibly early intervention in these systems can lower blood pressure effectively and give specific tools for primary prevention strategies
- Healt Condition(s) or Problem(s) studiedPre-eclampsia
- Inclusion criteria1. Patient is a female between 18 and 45 years of age on the day of signing informed consent.
2. Have a recent history of preeclampsia that is defined as gestational hypertension and concomitant proteinuria in the second half of pregnancy. Gestational hypertension was defined according to the criteria of the International Society for the Study of Hypertension in Pregnancy (ISSHP) as diastolic blood pressure above 90 mmHg and/or systolic blood pressure above 140 mmHg, measured on two or more separate occasions at least 4 hours apart. Proteinuria was diagnosed with urinary protein was above 300 mg per 24 hour or above 2+ at dipstick urinalysis 17
3. All patients should fulfil the following diagnostic criterion:
- Off treatment SBP > 120 mmHg and/or DBP > 80 mmHg during both visits.
4. Blood pressure is assessed by office readings in accordance with current guidelines for hypertension diagnosis18. The patient needs to be seated some minutes before and during the measurement. The cuff size should be adjusted to the patients’ arm circumference and needs to be on the same height level as the patients’ sternum during the measurements. Blood pressure is determined to a 2-mmHg accuracy-level. Blood pressure is measured on both arms during the first visit. If both measurements differ more than 10 mmHg, the highest value is taken. After at least 15 seconds, the measurement is repeated during the same visit. The highest mean of the two measurements on the same arm is considered as the actual blood pressure value.
5. Patient understands the study procedures, alternative treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.
- Exclusion criteria1. SBP > 180 mmHg and/or DBP > 110 mmHg during one or more screening measurements.
2. Current pregnancy
3. Current smoking or smoking during the previous 3 months
4. Use of “recreational” or illicit drugs
5. Recent history (within the last year) of alcohol abuse or dependence.
6. History of hypersensitivity reactions or intolerance to any (components of) medication used in this trial.
7. Current / recent participation (within 30 days of signing informed consent) in a study with an investigational compound or device.
8. Laboratory values as listed below:
a. Hemoglobin (Hb) < 8,6 mmol/L
b. TSH <0.3 mcIU/mL or > 5.0 mcIU/mL
c. MDRD < 60 mL/min/1,73m2
9. Medical conditions as listed below:
a. Resistant hypertension (blood pressure above target level, despite 3 antihypertensives, including a diuretic)
b. Secondary hypertension
c. Congestive Heart Failure
d. Atherosclerotic vascular disease. (As per NCEP ATP III and AHA/ACC Guidelines: Established atherosclerotic vascular disease includes history of myocardial infarction, stable angina, coronary artery procedures (angioplasty or bypass surgery) or evidence of clinically significant myocardial ischemia. Other atherosclerotic vascular disease includes clinical manifestations of non-coronary forms of atherosclerotic disease (peripheral arterial disease, cerebrovascular disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery]).
e. Cardiac arrhythmia’s, for example bradycardia, atrial fibrillation, sick-sinus syndrome, sinoatrial block, atrioventricular block or any other arrhythmia.
f. Obstructive sleep apnea syndrome (OSAS) or a score of 10 or higher on the Epworth Sleepiness Scale questionnaire 19 (see: appendix)
g. Serious liver function disorders (Child-Pugh-Class C).
h. COPD (GOLD classification of severity 2 or higher)
i. Celiac disease or other significant intestinal malabsorption
j. Malignancy ≤ 5 years prior to signing informed consent, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer.
k. Mental instability or major psychiatric illness
l. Polyneuropathy or clinical suspicion for autonomic nervous system dysfunction.
m. Any diseases that would limit or complicate study evaluation or participation.
n. Any diseases or screening abnormalities that call for treatment that cannot be postponed until after the study period without causing harm.
10. Any concomitant medication, particularly antihypertensive co-medication, glucose lowering medication, lipid lowering drugs, systemic corticosteroids and vitamin C or E supplements, but also any other kinds of drugs, including over the counter medication. Exceptions can be made for the following categories of drugs:
a. paracetamol;
b. proton-pump inhibitors;
c. topical creams and unguents that do not lead to significant uptake of the active components into the circulation (in case of steroid creams: class II or lower);
d. inhalation medication, nasal sprays and eye drops that do not lead to uptake of any of the active components into the circulation.
- mec approval receivedno
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupCrossover
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-sep-2014
- planned closingdate1-sep-2017
- Target number of participants30
- InterventionsOnce daily doses of losartan (100 mg), moxonidine (0,4 mg), low sodium diet (50 mmol NaCl/24 hour) and placebo following standardised 8-week treatment schedules. Participants receive all four interventions in a randomized and blinded (except from low sodium diet).
- Primary outcomemean 24-hour SBP/DBP, mean day/night time SBP/DBP
- Secondary outcomemean intrapersonal changes in endothelial function (FMD), serum lipid concentrations, HOMA, central blood pressure (PWA), serum and urine concentrations of markers of oxidative stress, serum concentrations of markers of systemic inflammation, arterial stiffness (PWV, PWA), RAAS-hormone concentrations, HRV, 24hr urine measurements
- TimepointsStudy is set up into 4 treatment arms of 8 weeks each.
- Trial web site
- statusplanned
- Sponsor/Initiator University Medical Center Utrecht (UMCU), AZU
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD9-mei-2014 - 4-jun-2014

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar